Summary for ENCSR689KKY

doi:10.17989/ENCSR689KKY

Summary

Status
released
Description
Reference epigenome for human H7-derived cardiovascular progenitor cell
Donor diversity
single
Assay
DNase-seq, ChIP-seq
Target
H3K27me3, H3K36me3, H3K4me3
Biosample summary
Homo sapiens cardiovascular progenitor cell originated from H7 treated with 5 ng/mL Fibroblast growth factor 2 for 5 days, 10 ng/mL Bone morphogenetic protein 4 for 5 days, 6 ng/mL Activin A for 5 days
Diseases
Not reported
Treatments
Activin A, Bone morphogenetic protein 4, Fibroblast growth factor 2

Attribution

ENCODE3 project
Lab
ENCODE Consortium
Award
U41HG006992 (J. Michael Cherry, Stanford)
Project
ENCODE
External resources

Experiments in ENCSR689KKY

Experiments
4 experiments
Accession
Assay
Target
Biosample summary
Lab
Status
Cart
ENCSR000DSGChIP-seqH3K36me3Homo sapiens cardiovascular progenitor cell originated from H7 treated with 5 ng/mL Fibroblast growth factor 2 for 5 days, 10 ng/mL Bone morphogenetic protein 4 for 5 days, 6 ng/mL Activin A for 5 daysJohn Stamatoyannopoulos, UW
released
ENCSR000DSKChIP-seqH3K27me3Homo sapiens cardiovascular progenitor cell originated from H7 treated with 5 ng/mL Fibroblast growth factor 2 for 5 days, 10 ng/mL Bone morphogenetic protein 4 for 5 days, 6 ng/mL Activin A for 5 daysJohn Stamatoyannopoulos, UW
released
ENCSR000DSOChIP-seqH3K4me3Homo sapiens cardiovascular progenitor cell originated from H7 treated with 5 ng/mL Fibroblast growth factor 2 for 5 days, 10 ng/mL Bone morphogenetic protein 4 for 5 days, 6 ng/mL Activin A for 5 daysJohn Stamatoyannopoulos, UW
released
ENCSR000EMWDNase-seqHomo sapiens cardiovascular progenitor cell originated from H7 treated with 5 ng/mL Fibroblast growth factor 2 for 5 days, 10 ng/mL Bone morphogenetic protein 4 for 5 days, 6 ng/mL Activin A for 5 daysJohn Stamatoyannopoulos, UW
released
Control experiments
1 control experiment
Accession
Control type
Biosample summary
Lab
Status
Cart
ENCSR000DSBinput libraryHomo sapiens cardiovascular progenitor cell originated from H7 treated with 5 ng/mL Fibroblast growth factor 2 for 5 days, 10 ng/mL Bone morphogenetic protein 4 for 5 days, 6 ng/mL Activin A for 5 daysJohn Stamatoyannopoulos, UW
released